Category Archives: compliance

Open Payments: A New Dawn for Transparency

The Physicians Payment Sunshine Act, more formally referred to as Open Payments, has been in place for almost 18 months. It is only in the next few months, however, that the implications of the law and its contentious requirements will start to be fully realised. Michael Christel reports.
Also posted in Events, FDA, Meetings, Regulatory | Tagged , , , , , | Leave a comment

Making the Most of Social Media (Within FDA’s New Guidelines)

By Ken Ribotsky. Pharmaceutical companies have begun using social media for business needs and promotion, yet have been hesitant to become too engaged since the FDA’s stance on social media activity remained unclear. But now that we know the FDA’s specific guidelines for pharma companies’ actions online, it’s time for brands to consider diving into […]
Also posted in E-Media, FDA, Guest Blog, Op-Ed, Regulatory, social media | Tagged , | 1 Comment

Eight Lessons for Enhancing Compliance Effectiveness in Europe

Andy Bender and Geert van Gansewinkel outline eight lessons for executing a soft change program for enhancing compliance effectiveness within European life sciences organizations. The European compliance and transparency landscape has changed rapidly over the last couple of years. Over and above the challenging compliance landscape, there is additional complexity impacting transparency relating to the […]
Also posted in Europe, Global, Guest Blog | Tagged , , , | Leave a comment

European Pharma Must Get Its Data in Order

New data maintenance guidelines have sparked a flurry of activity in Europe. Organizations are still grappling with electronic submissions, and the need to update data is intensifying the pressure. But there is an upside, says Miranda Pothiawala. Earlier this year formal guidelines on how to maintain and update data submitted to the extended EudraVigilance Medicinal […]
Also posted in Regulatory | Tagged , , , , , , | Leave a comment

Compliance Congress: Walking the Line

Pharma industry executives, FDA officials and Department of Justice attorneys speaking last week at CBI’s 11th annual Pharmaceutical Compliance Congress (PCC) offered solutions and threats to companies hoping to avoid enforcement actions.
Also posted in Advertising, Emerging Markets, FDA, Global, Legal, Manufacturing, Marketing, People, Regulatory, Sales, Strategy, Technology | Tagged , , , , , , , , , , , , , | Leave a comment
  • Categories

  • Meta